Xenios AG

Xenios AG operates as a medical technology company focused on extracorporeal heart and lung support. The company was established in 2013 through the merger of Novalung GmbH and Medos Medizintechnik AG. Dr. Georg Matheis and Juergen Boehm are named as founders. This formation was driven by the venture capital group zfhn Zukunftsfonds Heilbronn, which had previously acquired Novalung in 2008 and Medos in 2010. A significant milestone in the company's history was its acquisition by Fresenius Medical Care in late 2016, a move intended to combine Xenios's expertise in heart and lung support with Fresenius's leadership in dialysis and renal therapies. Following the acquisition, Xenios became the heart and lung business unit of Fresenius Medical Care.

The core of Xenios's business is providing advanced solutions for patients with cardiac and pulmonary failure. The company serves the critical care and intensive care unit (ICU) markets within hospitals worldwide. Its business model centers on the sale of medical devices and the associated patient kits to these healthcare facilities. The company develops, manufactures, and markets a comprehensive product range that functions on a single, common platform—the Xenios console. This platform is designed to provide extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS), which are vital for patients whose heart or lungs are unable to function adequately. These systems support the gas exchange in the lungs and the cardiovascular system, granting physicians more time for diagnosis and treatment. The product line includes various patient kits, such as the Novalung kits, tailored for different needs from CO2 removal to full oxygenation for patients ranging from neonates to adults. A key feature of these kits is the x.ellence® coating, a multi-layer coating of heparin and albumin on all blood-contact surfaces. In 2024, the company introduced the Xenios 2.0 system, featuring a simplified user interface, enhanced safety features, and improved data connectivity for integration with patient monitoring systems.

Xenios's strategic direction has been marked by several key events. In 2015, it received a seed round investment from Zukunftsfonds Heilbronn. After being acquired by Fresenius Medical Care, the company continued its global expansion, particularly targeting markets in North America and China. The integration with Fresenius Medical Care facilitates a multi-organ support strategy, connecting the Xenios console with Fresenius's MultiFiltratePro for combined lung and renal therapies. Regulatory approvals have been crucial for this expansion, including FDA clearance for the Novalung system in 2020 and approval for ECMO devices in China in 2021. The full integration of Novalung GmbH and Medos Medizintechnik GmbH into Xenios AG was completed in 2019 and 2022, respectively, consolidating its operational structure.

Keywords: extracorporeal life support, ECMO, heart-lung support, medical technology, cardiac failure, pulmonary failure, critical care, intensive care unit, Novalung, Medos, Xenios console, multi-organ support, extracorporeal membrane oxygenation, medical devices, dialysis, renal support, cardiovascular support, respiratory support, minimally invasive therapies, artificial lungs, blood pump systems